阿里健康全网独家首发：婴儿血管瘤外用原研药贝美净马来酸噻吗洛尔凝胶

Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1][3] - Beimeijing® is the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas," marking a critical leap for China in this medical field [3] - The drug's launch coincides with the issuance of the first overseas drug price certification by the National Drug Price Registration System, establishing a traceable price benchmark for Chinese innovative drugs in the international market [3] Clinical Need - Infantile hemangiomas are the most common benign tumors in infants, with an estimated global incidence of 5%-12%, and superficial types accounting for nearly 70% [3][4] - The "golden window period" for effective intervention is within the first 1-6 months after birth, during which rapid proliferation occurs [3][4] - Failure to intervene during this period can lead to permanent skin issues, even if the tumor eventually regresses naturally [4] Innovation and Development - The development of Beimeijing® was based on core patents from a team at Shanghai Jiao Tong University School of Medicine and involved a comprehensive process from molecular design to clinical validation [4][5] - The gel formulation allows for localized application, minimizing systemic exposure and enhancing safety for infants, which is particularly important given their delicate skin [5] - Clinical trial data showed a 60.7% clinical cure rate and an overall efficacy rate of 89.4% after 24 weeks of treatment in infants aged 1-6 months, demonstrating the drug's safety and effectiveness [5] Market Strategy - Alibaba Health is positioned as the launch platform for innovative Chinese drugs, utilizing user insights and digital technology to create a comprehensive service ecosystem for families in need [5] - The collaboration aims to deliver standardized treatment solutions and foster a patient-centered service model for ongoing management of infantile hemangiomas [5]